TITLE

Effect of Potassium Infusion on the Human Conduction System

AUTHOR(S)
Gould, Lawrence; Reddy, C. V. Ramana; Becker, William H.; Kim, S. G.
PUB. DATE
October 1980
SOURCE
Angiology;Oct1980, Vol. 31 Issue 10, p666
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
His bundle electrograms were recorded in 12 patients before and after the intravenous administration of 5 mEq of potassium. Antegrade and retrograde refractory periods were determined with the extrastimulus technique. The AH interval was 84 ± 7 msec before and 89 ± 7 msec after potassium (P < 0.05). The All interval at an atrial pacing rate of 140/minute was 129 ± 13 msec be- fore and 143 ± 16 msec after potassium (P < 0.02). The effective refractory period of the atrium was 264 ± 9 msec before and 280 ± 9 msec after potassium (P < 0.001). Thus small amounts of potassium delay conduction at the atrial and AV nodal level.
ACCESSION #
16400829

 

Related Articles

  • Impact of prophylactic i.v.magnesium on the efficacy of ibutilide for conversion of atrial fibrillation or flutter. Kalus, James S.; Spencer, Anne P.; Tsikouris, James P.; Chung, Jenny O.; Kenyon, Kenneth W.; Ziska, Martin; Kluger, Jeffrey; White, C. Michael // American Journal of Health-System Pharmacy;11/15/2003, Vol. 60 Issue 22, p2308 

    Examines the impact of prophylactic intravenous magnesium on the efficacy of ibutilide for conversion of atrial fibrillation and flutter to normal sinus rhythm. Rate of administration of direct-current cardioversion; Occurrence of ventricular arrhythmia; Rates of successful cardioversion;...

  • Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk. Haas, Sylvia; Bode, Christoph; Norrving, Bo; Turpie, Alexander G. G. // Vascular Health & Risk Management;2014, Vol. 10, p101 

    Rivaroxaban is a direct factor Xa inhibitor that is widely available to reduce the risk of stroke or systemic embolism in patients with nonvalvular atrial fibrillation and one or more risk factors for stroke. Rivaroxaban provides practical advantages compared with warfarin and other vitamin K...

  • A Randomized Trial of Pharmacogenetic Warfarin Dosing in Naïve Patients with Non-Valvular Atrial Fibrillation. Pengo, Vittorio; Zambon, Carlo-Federico; Fogar, Paola; Padoan, Andrea; Nante, Giovanni; Pelloso, Michela; Moz, Stefania; Frigo, Anna Chiara; Groppa, Francesca; Bozzato, Dania; Tiso, Enrico; Gnatta, Elisa; Denas, Gentian; Padayattil Jose, Seena; Padrini, Roberto; Basso, Daniela; Plebani, Mario // PLoS ONE;12/28/2015, Vol. 10 Issue 12, p1 

    Genotype-guided warfarin dosing have been proposed to improve patient’s management. This study is aimed to determine whether a CYP2C9- VKORC1- CYP4F2-based pharmacogenetic algorithm is superior to a standard, clinically adopted, pharmacodynamic method. Two-hundred naïve patients with...

  • Commentary. Garcia, David; Hylek, Elaine // Evidence Based Medicine;Apr2007, Vol. 12 Issue 2, p57 

    The author comments on a study which investigates whether the contemporary bleeding risk model can predict major bleeding in patients with atrial fibrillation (AT) who are receiving warfarin therapy. It is asserted that the model accurately predicts the patient's risk of major bleeding, enabling...

  • Amiodarone to prevent AF recurrence.  // Caribbean Health;Oct2000, Vol. 3 Issue 3, p25 

    The article focuses on the efficacy of low-dose amiodarone to prevent atrial fibrillation. There were 403 patients randomized to amiodarone 10 milligram daily for 14 days, 201 patients to sotalol 300 milligram daily for four weeks, and 200 milligram daily of propafenone. Many of them discontinue...

  • Rate control is better than rhythm control in atrial fibrillation.  // BMJ: British Medical Journal (International Edition);3/8/2003, Vol. 326 Issue 7388, p508 

    Presents a question and synopsis regarding the preferred strategy in high risk patients with atrial fibrillation: rate control or rhythm control strategy. Goal to keep patients in normal sinus rhythm; Need for multiple episodes of cardioversion and potentially toxic antiarrhythmic drugs;...

  • SAFETY AND OUTCOME OF INTRAVENOUS THROMBOLYSIS WITH rtPA IN PATIENTS WITH ATRIAL FIBRILLATION. Terecoasa, Elena; Tiu, Cristina; Guillan, Marta; Sanchez-Gonzalez, Victor; de Lecinana, Maria Alonso; Masjuan, Jaime // Romanian Journal of Neurology;2012, Vol. 11 Issue 3, p115 

    Background and purpose. Intravenous administration of recombinant tissue plasminogen activator (rtPA) is approved for the treatment of patients with acute ischemic stroke. It is still controversial if in patients with ischemic stroke due to atrial fibrillation this treatment has the same...

  • Corticosteroids prevented atrial fibrillation after cardiac surgery: COMMENTARY. Knight, Bradley P. // ACP Journal Club;Sept/Oct2007, Vol. 147 Issue 2, p36 

    The article reports on prevention of atrial fibrillation by using corticosteroids after cardiac surgery in patients. It reports on evidences favoring that inflammation is related to a higher risk for atrial fibrillation. By giving intravenous hydrocortisone from the evening after cardiac surgery...

  • Intravenous bisphosphonate therapy and atrial fibrillation/flutter risk in cancer patients: a nationwide cohort study. Erichsen, R; Christiansen, C F; Frøslev, T; Jacobsen, J; Sørensen, H T // British Journal of Cancer;9/27/2011, Vol. 105 Issue 7, p881 

    Background:There is conflicting evidence regarding bisphosphonates and atrial fibrillation (AF) risk in osteoporosis patients. However, bisphosphonates are used in much higher doses in treatment of bone metastasis and hypercalcemia, but little is known about the AF risk in cancer...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics